To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.

United States117th CongressHR-7658House of Representatives
Updated: May 3, 2022

Summary

This bill reauthorizes through FY2027 the Food and Drug Administration's Critical Path Public-Private Partnerships, which support medical product innovation, development, and safety.

Bill texts

Available versions
Introduced (House)View official text

1 version available

All available records shown.

Timeline

Latest companion bill action

S-4152: A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

  1. Referred to the House Committee on Energy and Commerce.

    House of Representatives

  2. Introduced in House

All available records shown.